Staff shortages at regulatory agencies and potentially overzealous “weeding” of products are two of the issues affecting expedited programs in their mission to deliver accelerated access to innovative new medicines in the US, EU and UK, said regulators at a symposium last week..
Expedited programs are designed to facilitate and speed up the development and review of new drugs that address, for example, unmet medical needs or which offer a breakthrough in treatment
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?